122 related articles for article (PubMed ID: 38824444)
1. Accounting for the Discrepancies in Treatment Completion and SVR in OPPORTUNI-C.
El-Dalati S; Stoner BJ
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38824444
[No Abstract] [Full Text] [Related]
2. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
3. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.
Dimova RB; Zeremski M; Jacobson IM; Hagan H; Des Jarlais DC; Talal AH
Clin Infect Dis; 2013 Mar; 56(6):806-16. PubMed ID: 23223596
[TBL] [Abstract][Full Text] [Related]
4. Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy.
Cooper MP; Foley H; Damico D; Wright M; Rhudy C; Schadler A; Platt T
J Manag Care Spec Pharm; 2022 Jun; 28(6):667-672. PubMed ID: 35621721
[No Abstract] [Full Text] [Related]
5. Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial.
Midgard H; Malme KB; Pihl CM; Berg-Pedersen RM; Tanum L; Klundby I; Haug A; Tveter I; Bjørnestad R; Olsen IC; Finbråten AK; Dalgard O
Clin Infect Dis; 2024 Mar; 78(3):582-590. PubMed ID: 37992203
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020.
Beiser ME; Shaw LC; Wilson GA; Muse KO; Shores SK; Baggett TP
J Gen Intern Med; 2023 Mar; 38(4):865-872. PubMed ID: 36127534
[TBL] [Abstract][Full Text] [Related]
8. Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response.
Barut S; Günal O; Erkorkmaz U
Scand J Infect Dis; 2012 Oct; 44(10):761-5. PubMed ID: 22681186
[TBL] [Abstract][Full Text] [Related]
9. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C.
Cohen SM; Kwasny MJ; Ahn J
Ann Pharmacother; 2009 Feb; 43(2):202-9. PubMed ID: 19193591
[TBL] [Abstract][Full Text] [Related]
10. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
11. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment.
Janda M; Mergenhagen KA
Psychosomatics; 2017; 58(6):624-632. PubMed ID: 28870488
[TBL] [Abstract][Full Text] [Related]
13. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
[TBL] [Abstract][Full Text] [Related]
14. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
15. The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
Nadia K; Hicham E; Reda TM; Nadia T; Elarbi B; Saâd E; Mimoun Z; Saâd M
Gene; 2015 Aug; 568(1):31-4. PubMed ID: 25958342
[TBL] [Abstract][Full Text] [Related]
16. Retrospective chart review to assess the relationship between depression and sustained virological response from interferon treatment for hepatitis C virus.
Wackernah RC; Lou M; Park SH
Clin Ther; 2011 Oct; 33(10):1400-5. PubMed ID: 21982383
[TBL] [Abstract][Full Text] [Related]
17. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Drysdale K; Ntuli Y; Bestwick J; Gelson W; Agarwal K; Forton D; Mutimer D; Elsharkawy AM; Townley C; Mahomed F; Foster GR
Aliment Pharmacol Ther; 2020 Jul; 52(1):168-181. PubMed ID: 32441382
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients.
Miyaki E; Imamura M; Hiraga N; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Chayama K
Hepatol Res; 2016 Jul; 46(8):758-64. PubMed ID: 26574180
[TBL] [Abstract][Full Text] [Related]
19. Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
Marshall MC; Herrera JL
Dig Dis Sci; 2018 Dec; 63(12):3228-3232. PubMed ID: 30128645
[TBL] [Abstract][Full Text] [Related]
20. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
